[1] 胡郑君, 胡红梅, 张亮. 玻璃体腔Bevacizumab注射后联合二联术治疗新生血管性青光眼[J]. 国际眼科杂志, 2015, 15(5): 892.
[2] 史志洁, 张金嵩, 吕晓贝. 玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J]. 眼科新进展, 2016, 36(8): 751.
[3] 徐韶琳, 王英, 苏冠方. 不同手术方式治疗新生血管性青光眼疗效观察[J]. 眼科研究, 2007, 25(9): 707.
[4] KOBAYASHI S, INOUE M, YAMANE S, et al. Long-term outcomes after preoperative intravitreal injection of bevacizumab before trabeculectomy for neovascular glaucoma[J]. J Glaucoma, 2016, 25(3): 281. doi: 10.1097/IJG.0000000000000211
[5] SAITO Y, HIGASHIDE T, TAKEDA H, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma[J]. Acta Ophthalmol, 2010, 88(1): 96. doi: 10.1111/j.1755-3768.2009.01648.x
[6] GUPTA V, JHA R, RAO A, et al. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma[J]. Eur J Ophthalmol, 2009, 19(3): 435. doi: 10.1177/112067210901900318
[7] ZHANG M, ZHANG J, YAN M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys[J]. Mol Vis, 2008, 14(4): 37.
[8] ROSENFELD PJ, SCHWARTZ SD, BLUMENKRANZ MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration[J]. Ophthalmology, 2005, 112(6): 1048. doi: 10.1016/j.ophtha.2005.01.043
[9] 蔡锡安, 彭惠. 两种抗VEGF药物治疗渗出性年龄相关性黄斑病变的疗效[J]. 国际眼科杂志, 2016, 16(8): 1501.
[10] LIU L, XU YF, HUANG Z, et al. Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications[J]. BMC Ophthalmol, 2016, 16(1): 1. doi: 10.1186/s12886-015-0180-2
[11] LÜKE J, NASSAR K, LVKE M, et al. Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma-results from a prospective interventional case series[J]. Graefes Arch Clin Exp Ophthalmol, 2013, 251(10): 2403. doi: 10.1007/s00417-013-2428-y